TAU makes breakthrough in drug delivery to treat inflammatory bowel disease
To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...
Psoriasis Linked to Gut Inflammation and Increased Risk of Crohn’s Disease
Understanding the link between gut health and psoriasis opens new avenues for treatment and highlights the need for comprehensive care approaches that encompass both dermatological and gastrointestina ...
MedPage Today1d
Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD
SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...
MedPage Today1d
Exclusion Diet in Pediatric Crohn's Tied to Clinical Remission in Small Study
SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...
Healio2d
Q&A: IBD wearable alerts patients ‘in real time’ about impending disease flares
IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...
BlackDoctor2d
Crohn’s Disease, Black People, and the Barriers we Face
Let's dive deep into a topic that isn’t getting enough shine – Crohn's disease and how it's hitting the Black community.
Hosted on MSN2d
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
Engineered to specifically act on the vascular endothelial growth factor receptor 2 (VEGFR2), BR55 (perfluorobutane/nitrogen ...
Eli Lilly reports sustained Crohn's disease treatment success
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Malaysian Reserve2d
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®
Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...
Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...